Absolute contraindications: Known allergy to either peptide or its components Active cancer (insufficient safety data) Pregnancy or breastfeeding (insufficient safety data) Severe immunocompromise (theoretical concern) Relative contraindications (require careful consideration): History of cancer (consult a medical advisor) Major cardiac disease (monitor closely) Severe liver or kidney disease (may affect clearance) Active infections (wait until resolved) Bleeding disorders (monitor injection sites carefully) Special populations: Elderly subjects: usually well tolerated, no dose adjustment needed Subjects with multiple conditions: enhanced monitoring recommended Those on multiple medications: review for possible interactions Drug Interactions The peptides have minimal documented drug interactions
There is also a patent (US20020183255A1) specifically covering the use of KPV for dermatological disorders, including eczematous dermatitis
It can be observed that proglucagon is not expressed by a single gene, but is embedded in a larger gene, and when this large gene expresses a large peptide chain (called preprohormones), it is then cleaved by specific enzymes and post-translationally modified to finally obtain fragments with different biological activities
Ethical Approval The study protocol was approved by appropriate health authorities according to local guidelines and by an institutional review board/independent ethics committee
Hayes A, Nixon I, Strauss D